N
PHAT icon

Numerai’s Phathom Pharmaceuticals PHAT Stock Holding History

Numerai’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,264
Closed -$124K – 571
2024
Q4 		$124K Sell
15,264
-34,063
-69% -$422K 0.03% 373
2024
Q3 		$892K Buy
+49,327
New +$689K 0.24% 146

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Numerai's PHAT Position: Q1 2025 in Review

Numerai sold out of Phathom Pharmaceuticals (PHAT) in Q1 2025, closing a stake of 15,264 shares — an estimated $124K sold.

Numerai first reported a position in PHAT in Q3 2024 and held it in 2 quarters. The position peaked at $892K in Q3 2024. 137 funds tracked by Wall St. Rank hold PHAT as of Q1 2025.

  • Numerai reported no remaining Phathom Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Numerai sold 15,264 Phathom Pharmaceuticals shares in Q1 2025, an estimated $124K.
  • Numerai first reported a position in Phathom Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Numerai's Phathom Pharmaceuticals position peaked at $892K in Q3 2024.
  • 137 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2025.

Based on Numerai's 13F filing for Q1 2025, filed 15 May 2025.